Akoya Biosciences (AKYA) Stock Price, News & Analysis

Company Overview

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Key Stats

• Today's Range: $1.29 to $1.29
• 50-Day Range: $1.12 to $1.37
• 52-Week Range: $0.93 to $3.42
• Volume: N/A
• Average Volume: 416,191 shs
• Market Capitalization: $64.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.38
• Consensus Rating: Hold

AKYA Stock Analysis - Frequently Asked Questions

How were Akoya Biosciences' earnings last quarter?

Akoya Biosciences, Inc. (NASDAQ:AKYA) posted its quarterly earnings results on Monday, May, 12th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.03. The business earned $16.64 million during the quarter, compared to analysts' expectations of $20.19 million. Akoya Biosciences had a negative net margin of 59.44% and a negative trailing twelve-month return on equity of 487.85%.

When did Akoya Biosciences IPO?

Akoya Biosciences (AKYA) raised $125 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 6,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity served as the underwriters for the IPO.

Who are Akoya Biosciences' major shareholders?

Top institutional investors of Akoya Biosciences include Geode Capital Management LLC (0.49%), JPMorgan Chase & Co. (0.28%), JBF Capital Inc. (0.24%) and Marshall Wace LLP (0.15%). Insiders that own company stock include Matthew Winkler, Garry PhD Nolan, Brian Mckelligon, John Frederick Ek, Frederic Pla and Joseph Driscoll.
View institutional ownership trends.

What other stocks do shareholders of Akoya Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akoya Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 9/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:AKYA
• CIK: 1711933
• Web: www.akoyabio.com
• Phone: 855-896-8401
• Fax: N/A
• Employees: 90
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Akoya Biosciences: $2.38
• High Price Target: $5.00
• Low Price Target: $1.08
• Potential Upside/Downside: +84.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.37 million
• Net Margins: -59.44%
• Pretax Margin: -59.28%
• Return on Equity: -487.85%
• Return on Assets: -35.86%

Debt

• Debt-to-Equity Ratio: 10.12
• Current Ratio: 0.61
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: $79.96 million
• Price / Sales: 0.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 8.60

Miscellaneous

• Outstanding Shares: 49,954,000
• Free Float: 46,307,000
• Market Cap: $64.44 million
• Optionable: Optionable
• Beta: 1.36